A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Intravenous CR845 in Hemodialysis Patients, and Its Safety and Efficacy in Hemodialysis Patients With Uremic Pruritus

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Intravenous CR845 in Hemodialysis Patients, and Its Safety and Efficacy in Hemodialysis Patients With Uremic Pruritus

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Cara Therapeutics
  • Most Recent Events

    • 29 Jun 2016 Results published in a Cara Therapeutics media release.
    • 10 Mar 2016 According to a Cara Therapeutics media release, data from this study were presented at Kidney Week 2015, the American Society of Nephrology's Annual Meeting, in November 2015.
    • 22 Sep 2015 According to a Cara Therapeutics media release, data from this trial will be presented at the 8th World Congress on Itch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top